share_log

TransMedics | 8-K: TransMedics Reports Second Quarter 2024 Financial Results

TransMedics | 8-K: TransMedics Reports Second Quarter 2024 Financial Results

TransMedics | 8-K：TransMedics公佈2024年第二季度財務業績
美股SEC公告 ·  2024/08/01 05:12

牛牛AI助理已提取核心訊息

TransMedics reported strong Q2 2024 financial results with total revenue reaching $114.3M, up 118% YoY from $52.5M. The company achieved net income of $12.2M ($0.35 per diluted share), compared to a net loss of $1.0M in Q2 2023. Gross margin was 61%, down from 70% in the prior year due to higher service revenue proportion.Growth was primarily driven by increased utilization of the Organ Care System across all organs through the National OCS Program and the launch of TransMedics logistics services. The company's operational expansion included owning 15 aircraft by quarter-end, with two additional aircraft purchased in July 2024. Operating expenses increased to $56.8M from $37.6M YoY, reflecting investments in R&D and organizational growth.Given the strong performance, TransMedics raised its full-year 2024 revenue guidance to $425M-$445M, representing 76-84% growth compared to 2023, up from previous guidance of $390M-$400M. The company maintained a strong financial position with cash of $362.8M as of June 30, 2024.
TransMedics reported strong Q2 2024 financial results with total revenue reaching $114.3M, up 118% YoY from $52.5M. The company achieved net income of $12.2M ($0.35 per diluted share), compared to a net loss of $1.0M in Q2 2023. Gross margin was 61%, down from 70% in the prior year due to higher service revenue proportion.Growth was primarily driven by increased utilization of the Organ Care System across all organs through the National OCS Program and the launch of TransMedics logistics services. The company's operational expansion included owning 15 aircraft by quarter-end, with two additional aircraft purchased in July 2024. Operating expenses increased to $56.8M from $37.6M YoY, reflecting investments in R&D and organizational growth.Given the strong performance, TransMedics raised its full-year 2024 revenue guidance to $425M-$445M, representing 76-84% growth compared to 2023, up from previous guidance of $390M-$400M. The company maintained a strong financial position with cash of $362.8M as of June 30, 2024.
TransMedics公佈了2024年第二季度的強勁財務業績，總營業收入達到11430萬美元，同比增長118%，而2023年第二季度爲5250萬美元。公司實現了凈利潤1220萬美元（每股攤薄收益0.35美元），相比於2023年第二季度的淨虧損100萬美元。毛利率爲61%，低於去年的70%，主要是由於服務收入比例的提高。增長主要得益於通過國家OCS計劃對各類器官的器官護理系統使用率的增加，以及TransMedics物流服務的推出。公司的運營擴展包括在本季度末擁有15架飛機，2024年7月還額外購買了兩架飛機。營業費用從去年的3760萬美元增加到5680萬美元，反映了在研發和組織擴展方面的投資。鑑於強勁的表現，TransMedics將其2024年全年的營業收入指導提高至42500萬至44500萬美元，同比增長76-84%，而之前的指導爲39000萬至40000萬美元。到2024年6月30日，公司保持了強勁的財務狀況，現金爲36280萬美元。
TransMedics公佈了2024年第二季度的強勁財務業績，總營業收入達到11430萬美元，同比增長118%，而2023年第二季度爲5250萬美元。公司實現了凈利潤1220萬美元（每股攤薄收益0.35美元），相比於2023年第二季度的淨虧損100萬美元。毛利率爲61%，低於去年的70%，主要是由於服務收入比例的提高。增長主要得益於通過國家OCS計劃對各類器官的器官護理系統使用率的增加，以及TransMedics物流服務的推出。公司的運營擴展包括在本季度末擁有15架飛機，2024年7月還額外購買了兩架飛機。營業費用從去年的3760萬美元增加到5680萬美元，反映了在研發和組織擴展方面的投資。鑑於強勁的表現，TransMedics將其2024年全年的營業收入指導提高至42500萬至44500萬美元，同比增長76-84%，而之前的指導爲39000萬至40000萬美元。到2024年6月30日，公司保持了強勁的財務狀況，現金爲36280萬美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間